McGuire Investment Group LLC Grows Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

McGuire Investment Group LLC lifted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 2.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 33,177 shares of the medical research company's stock after buying an additional 745 shares during the period. Thermo Fisher Scientific makes up 2.5% of McGuire Investment Group LLC's investment portfolio, making the stock its 15th largest holding. McGuire Investment Group LLC's holdings in Thermo Fisher Scientific were worth $16,509,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently bought and sold shares of TMO. Cypress Advisory Group LLC acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $253,000. Intact Investment Management Inc. grew its holdings in shares of Thermo Fisher Scientific by 34.0% during the fourth quarter. Intact Investment Management Inc. now owns 2,600 shares of the medical research company's stock worth $1,353,000 after buying an additional 660 shares during the last quarter. Purkiss Capital Advisors LLC acquired a new position in Thermo Fisher Scientific in the 4th quarter valued at about $1,121,000. LaFleur & Godfrey LLC raised its stake in Thermo Fisher Scientific by 9.1% during the 4th quarter. LaFleur & Godfrey LLC now owns 29,767 shares of the medical research company's stock valued at $15,486,000 after acquiring an additional 2,488 shares during the last quarter. Finally, GAMMA Investing LLC lifted its position in Thermo Fisher Scientific by 22.0% during the 1st quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company's stock worth $2,419,000 after acquiring an additional 877 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the sale, the executive vice president directly owned 23,167 shares of the company's stock, valued at $9,960,188.31. This trade represents a 1.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.33% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Wall Street Zen raised Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Wednesday, May 21st. UBS Group dropped their price objective on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating on the stock in a research note on Thursday, April 24th. Barclays cut their price objective on shares of Thermo Fisher Scientific from $475.00 to $450.00 and set an "equal weight" rating for the company in a research report on Tuesday, June 24th. Stifel Nicolaus dropped their price target on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research note on Thursday, April 24th. Finally, Argus cut their price target on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a report on Tuesday, April 29th. Four equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $604.05.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO traded down $2.45 during midday trading on Monday, hitting $405.83. 3,919,130 shares of the stock were exchanged, compared to its average volume of 1,959,714. The stock has a market cap of $153.20 billion, a P/E ratio of 23.80, a PEG ratio of 2.17 and a beta of 0.78. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $627.88. The company has a 50 day moving average price of $409.74 and a 200-day moving average price of $482.94. The company has a current ratio of 1.77, a quick ratio of 1.38 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. The company had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. During the same quarter in the prior year, the firm earned $5.11 earnings per share. The company's revenue for the quarter was up .2% compared to the same quarter last year. On average, research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.42%. The ex-dividend date of this dividend is Friday, June 13th. Thermo Fisher Scientific's payout ratio is currently 10.09%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.